Lymphocyte count has been associated with increased disease severity in COVID19. 1,2 Patients who died from COVID19 are reported to have had significantly lower lymphocyte counts than survivors. 2 As such, we need to consider the potential compounding immunological insults involved with initiation of an extracorporeal circuit in these patients. During ECMO, substantial decreases in the number and function of some populations of lymphocytes is commonplace. 3 As it might be hypothesised that repletion of lymphocytes could be key to recovery from COVID19, lymphocyte count should be closely monitored in these patients receiving ECMO.
Ruan and colleagues 2 also showed that interleukin6 (IL6) concentrations differed significantly between survivors and nonsurvivors of COVID19, with nonsurvivors having up to 1·7times higher values. During ECMO, IL6 concentrations are consistently elevated and inversely correlated with survival in children and adults. 4 Those that survived ECMO were able to normalise their IL6 concentrations, whereas those that died had persistently elevated values. Moreover, elevated IL6 concentrations in lung induced by initiation of ECMO have been convincingly shown to be associated with parenchymal damage in animal models of venovenous ECMO. 5 While not to discourage the use of ECMO, based on the abovementioned observations, the immunological status of patients should be considered when selecting candidates for ECMO. More reports are needed to understand the potential benefits or harms of extracorporeal life support in severe COVID19 and future authors should be encouraged to provide more data for this subset of patients. Lastly, clinicians should consider tracking both lymphocyte count and IL6 during ECMO to monitor patient status and prognosis. 
